Management
Treatment & prognosis
Because MdDS is a problem of adaptation, the most rational treatment is re-adaptation — retraining the reflex that went wrong. Drugs and neuromodulation play supporting roles.
An overview of the options
No single treatment works for everyone, and conventional vestibular suppressants are notably unhelpful — a useful negative clue. The mainstays target the maladapted central adaptation directly.
- Reassurance & educationSupportedExplaining the maladaptive-adaptation model; many transient, motion-triggered cases settle spontaneously.
- VOR readaptation (Dai protocol)SupportedFull-field optokinetic stripes viewed while the head is rolled at the patient's perceived rocking frequency — to 're-tune' the maladapted velocity-storage/roll adaptation.
- MedicationsAdjunctBenzodiazepines (clonazepam) can modestly suppress symptoms; SSRIs/SNRIs help some, especially with anxiety. Classic vestibular suppressants (e.g. meclizine) are typically ineffective — a useful negative clue.
- Neuromodulation (rTMS)EmergingRepetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex has shown symptom reduction in trials; still investigational.
- Vestibular rehabilitation & CBTAdjunctConventional vestibular rehabilitation has limited effect alone; cognitive-behavioural therapy addresses the substantial anxiety burden.
VOR readaptation — the Dai protocol
The most specific treatment retrains the balance reflex that got “stuck.” The patient watches moving stripes on a screen while gently rolling the head side to side, in time with their own rocking. Over a few sessions this can re-tune the brain back to normal.
The Dai readaptation protocol exposes the patient to full-field moving optokinetic stripes while the head is rolled at their perceived rocking frequency, directly re-training the maladapted roll-plane VOR. Trials report meaningful symptom relief in a large proportion of patients, especially the motion-triggered subtype.1,2
Readaptation is the most mechanism-specific therapy and is most effective in motion-triggered disease and when started earlier; benefit is lower in long-standing spontaneous-onset cases, and relapse can occur, sometimes prompting repeat treatment.2 It requires specialised equipment and remains available only in a few centres.
Medication & neuromodulation
Benzodiazepines (clonazepam) can modestly dampen symptoms by suppressing velocity storage, and SSRIs/SNRIs help some patients, particularly where anxiety is prominent — but classic vestibular suppressants such as meclizine are typically ineffective.4 Repetitive transcranial magnetic stimulation over the dorsolateral prefrontal cortex has reduced symptoms in trials and is a promising, still-investigational option.3 Conventional vestibular rehabilitation has limited effect alone, and CBT addresses the substantial anxiety burden.
Prognosis
Prognosis depends on subtype. Motion-triggered MdDS often improves over weeks to months and responds better to readaptation; spontaneous-onset disease is more likely to become chronic and refractory.5 Across both, reassurance, addressing comorbid anxiety, and avoiding the trap of escalating ineffective vestibular suppressants are central to good care.
Key points
- VOR readaptation (the Dai protocol) is the most mechanism-specific treatment — best in motion-triggered, earlier disease.
- Clonazepam and SSRIs/SNRIs help some; classic vestibular suppressants (meclizine) do not.
- rTMS over the DLPFC is a promising, investigational neuromodulation option.
- Conventional vestibular rehab is limited alone; CBT addresses anxiety.
- Motion-triggered MdDS has a better prognosis than the spontaneous form.